Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

BioConsul Retained by Takeda for Consulting Efforts in the U.S.


Business Editors & Health/Medical Writers

BIOWIRE2K

DANVILLE Danville.

1 City (1990 pop. 33,828), seat of Vermilion co., E Ill., on the Vermilion River at the Ind. line; inc. 1839. It is a commercial and industrial center in a dairy, farm, and coal area.
, Calif.--(BUSINESS WIRE)--Jan. 7, 2003

BioConsul Drug Development Corp. today announced that it has been retained by Takeda Takeda (武田氏 Takeda)  Chemical Industries Ltd.

Terms of the consulting and services agreement were not disclosed dis·close  
tr.v. dis·closed, dis·clos·ing, dis·clos·es
1. To expose to view, as by removing a cover; uncover.

2. To make known (something heretofore kept secret).
.

Under the agreement, BioConsul will consult for Takeda's license activities regarding various technical and financial aspects of U.S. biotechnology and biopharmaceutical companies.

"We greatly value the confidence Takeda has placed in BioConsul and look forward to a long, productive relationship," said Anthony Maida Maida can refer to:
  • Maida, a town and comune in the Province of Catanzaro, Calabria, Italy, which gave its name to the Plain of Maida and the 1806 Napoleonic Battle of Maida.
  • Maida flour Used in India to make various flatbreads and other bakery products
, III, chairman and founder of BioConsul.

Takeda is the largest pharmaceutical company in Japan and among the leaders in the world. Takeda discovers, develops, manufactures and markets a broad range of innovative products to improve the health and quality of life of people around the world.

BioConsul Drug Development Corp. leverages experienced resource management to develop promising biotechnology and biopharmaceutical candidate products and emerging companies. BioConsul supervises a full range of development services on behalf of its customers resulting in faster, cost-effective cost-effective,
n the minimal expenditure of dollars, time, and other elements necessary to achieve the health care result deemed necessary and appropriate.
, lower risk and optimal return on drug development investments. The company is located at 828 Eastbrook Eastbrook could refer to the following:
  • Eastbrook, Maine, a town in Hancock County, Maine, USA
  • Eastbrook High School, a public high school in Marion, Indiana, USA
  • Eastbrook railway station, a 2 platform train station located in Dinas Powys, Wales
 Court, Danville, Calif. 94506-1206; phone 925/736-1863; fax 925/736-5910; email amaida@bioconddc.com.
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:9JAPA
Date:Jan 7, 2003
Words:195
Previous Article:Georgia College & State University Secures Wireless Network for Entire Campus Plus Community 'Hot Spots' with Meetinghouse Solution.
Next Article:eHelp Introduces First Add-On Toolkit Complementary to Flash; Seven Powerful Add-On Tools Accelerate and Simplify Flash Development.
Topics:



Related Articles
Takeda Pharmaceutical to Acquire Rights to Develop and Commercialize DPP4 Inhibitor from US Pharmaceutical Company Pharmaceutical Product Development.
Takeda Pharmaceutical Receives FDA Fast Track Designation for TAK-242, Investigational Compound for Severe Sepsis.
Hitachi, Takeda Pharmaceutical to Establish Information System Service Joint Venture.
SageGroupAssociates.
Takeda Starts Phase 2 Clinical Studies of ATL-962, an Obesity and Related Disease Treatment, in Japan.
Takeda Pharmaceutical, Hitachi Jointly Establish New Information System Company for Medical and Pharmaceutical Businesses.
Takeda Pharmaceutical Wins Patent Infringement Case on ACTOS in US.
US District Court Dismisses Abbott Laboratories' Litigation Against Takeda Pharmaceutical.
Takeda Announces Start of Phase 3 Clinical Program in the U.S.of Fixed Dose Combination Product of Actos(R) + TAK-536for Treatment of Patients with...
A Once-weekly Formulation of Risedronate Sodium Hydrate, an Antiosteoporotic Agent, Was Approved.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles